Trump Orders Faster Psychedelic Research for Veterans' Mental Health
Executive order directs the FDA to speed review of psychedelics, designates $50 million for ibogaine research and opens a Right to Try pathway for qualifying patients.
World News GroupTrump greenlights psychedelic drug for human testing
Military TimesTrump clears path for expanded psychedelic research to treat veterans’ PTSD
CNBCHow Trump's psychedelics executive order could unlock stalled cannabis reform
Scientific AmericanTrump’s order on psychedelics could have far-reaching science consequences
Overview
President Donald Trump signed an executive order on Saturday directing the Food and Drug Administration to accelerate review of certain psychedelic therapies, including ibogaine.
The order aims to ease regulatory barriers that have limited U.S. research into Schedule I substances and to support treatments for severe mental illness and veteran suicide prevention.
Health Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and veterans who credited ibogaine with recovery joined or were cited at the signing and urged expanded research and access.
The order designates $50 million to ibogaine research, notes ibogaine is a Schedule I drug, and FDA Commissioner Marty Makary said the agency will prioritize trials and approved the first iboga investigational new drug clearance.
Implementation will proceed with FDA issuing national priority vouchers for breakthrough psychedelics, Right to Try access for qualifying patients, and further controlled trials to assess safety and effectiveness.
Analysis
Center-leaning sources frame the story as a medical- and research-first breakthrough, using legitimizing language emphasizing science, patients and health care, prioritizing industry voices (lawyers, CEOs) and market reactions while acknowledging safety concerns only briefly (Nora Volkow on ibogaine). Structural comparisons to stalled cannabis rescheduling reinforce a progress narrative.